Agree zecs..,
The regression in tumour is the main key ( no within trial time expiry). Efficacy is certainly evident on this pre-clinical animal study.
Of course, the synthesis is mainly what the market is currently comparing based on the clinical results of past announcements.
From the company’s perspective, the drug is providing more proof of activity as data shows, from many perspectives or trial exposures.
The company is keeping up the good ground work and keeping shareholders in the loop along the way (imo).
Add to My Watchlist
What is My Watchlist?
